Science and Technology Daily, Moscow, September 27 (Reporter Dong Yingbi) The Russian National Nuclear Research University cooperated with researchers from other institutions to develop a nanoprobe that can accurately deliver drugs to diseased tissues
Targeted delivery of drugs to specific tissues and cells is one of the most important directions for the treatment of focal diseases, including cardiovascular disease, cancer, tuberculosis, two types of diabetes, and other diseases
At present, the technology to create such systems in the world is in the early stage of development, and the key task is to study the drug delivery process
Researchers from the Nanobioengineering Laboratory of the Russian National Nuclear Research University and the Sechenov First State Medical University in Moscow, the National Medical Oncology Research Center of Blokhin, and the University of Reims-Champaign-Ardennes, France, jointly developed a new type of ultramicroscopic probe The needle meets all these conditions
This new type of nanoprobe consists of a photoluminescent nanocrystal (quantum dot) and acridine derivative molecules (a drug that helps the probe to penetrate the cell membrane) attached to its surface
Pavel Samohvalov, deputy director of the Nanobioengineering Laboratory of the National Nuclear Research University of Russia, said that quantum dots are fluorescent nanostructures used in some high-tech fields.
It is reported that the size of the new probe is about 15 nanometers, which is only one-hundreds to thousands of human cells
Pavel Samohvalov explained that this new type of nanoprobe is mainly used for experimental research to develop targeted delivery tools for anti-cancer drugs, and has become the prototype of this universal tool
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.